Skip to main content
. 2023 May 24;14(6):788–793. doi: 10.1021/acsmedchemlett.3c00079

Table 3. In Vitro Profiles of Compound 2.

graphic file with name ml3c00079_0007.jpg

  X1 X2 X3 R hNaV1.1 IC50 (μM)a hNaV1.5 IC50 (μM)a hNaV1.7 IC50 (μM)a mNaV1.7 IC50 (μM)a hERG inhibition at 100 μMa,b Log Dc Solubility (μM)d Mouse PB free (%)d
2a H H H c-Pr >100 >300 1.6 >10 –8.8 ± 3.1 NTe NTe NTf
2b H H H Me NTf >300 >10 NTf –0.1 ± 11.6 NTe NTe NTf
2c H F H c-Pr >100 >300 0.86 2.7 –1.1 ± 5.8 NTe NTe NTf
2d H Cl H c-Pr 9.9 107 0.085 0.46 34.1 ± 2.1 0.80 35 NTf
2e H CF3 H c-Pr 6.6 14 0.015 0.061 6.9 ± 9.0 1.0 130 0.50
2f CF3 H H c-Pr >100 210 0.059 1.6 21.0 ± 16.3 1.0 29 1.4
2g H CF3 F c-Pr 1.2 32 0.040 0.015 –2.9 ± 0.0 0.60 25 0.7
a

Data were obtained with a high-throughput electrophysiology system (IonWorks Quattro). Values are from a single experiment run in quadruplicate.

b

hERG inhibitory activity at 10, 30, and 100 μM was assessed, and the dose response was confirmed. Each value represents the mean ± SD.

c

Distribution coefficients (log D) were measured after partition between 1-octanol and PBS (pH = 7.4).

d

Unbound fractions (%) in mouse plasma.

e

Aqueous thermodynamic solubility at pH 6.8.

f

Not tested.